PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21557697-7 2011 Resistin mRNA expression in monocyte-derived macrophages was higher than that in mononuclear cells (p = 0.04), and could be reduced by rosiglitazone (p < 0.001). Rosiglitazone 135-148 resistin Homo sapiens 0-8 12504108-4 2003 Taqman analysis and Western blotting showed that rosiglitazone decreased resistin expression at both the mRNA and protein levels in human primary monocyte-derived macrophages in vitro. Rosiglitazone 49-62 resistin Homo sapiens 73-81 12504108-5 2003 Resistin expression was reduced by up to 80% after exposure to 100 nM rosiglitazone for 96 h. Bioinformatics analysis of the genomic sequence upstream of the resistin coding sequence identified several putative PPAR response elements of which one was shown to bind PPAR gamma using electrophoretic mobility shift assays. Rosiglitazone 70-83 resistin Homo sapiens 0-8 12504108-5 2003 Resistin expression was reduced by up to 80% after exposure to 100 nM rosiglitazone for 96 h. Bioinformatics analysis of the genomic sequence upstream of the resistin coding sequence identified several putative PPAR response elements of which one was shown to bind PPAR gamma using electrophoretic mobility shift assays. Rosiglitazone 70-83 resistin Homo sapiens 158-166 24094981-7 2013 Though there were conflicting findings of resistin in metabolic syndrome or type 2 diabetes mellitus in different studies, resistin was significant decreased in the rosiglitazone treated patients than in the metformin-treated patients in most of studies. Rosiglitazone 165-178 resistin Homo sapiens 123-131 17287417-12 2007 CONCLUSIONS: Rosiglitazone had beneficial effects on serum levels of adiponectin and resistin, suggesting that these adipocytokines may contribute to the improvement in insulin sensitivity observed during the treatment. Rosiglitazone 13-26 resistin Homo sapiens 85-93 17287417-0 2007 Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study. Rosiglitazone 0-13 resistin Homo sapiens 87-95 17287417-4 2007 The aim of this study was to examine the effects of 4 months of treatment with the insulin sensitizer rosiglitazone on plasma adiponectin, resistin and ghrelin levels in overweight women with PCOS. Rosiglitazone 102-115 resistin Homo sapiens 139-147 17892035-0 2007 [The effect of rosiglitazone on plasma adiponectin and resistin levels in obese PCO woman--preliminary report]. Rosiglitazone 15-28 resistin Homo sapiens 55-63 17892035-1 2007 AIM OF THE STUDY: to determine the effect of rosiglitazone on plasma adiponectin and resistin levels in obese, non-diabetic polycystic ovary (PCO) subjects and relationship between circulating adipocytokines, insulin resistance and lipid profile. Rosiglitazone 45-58 resistin Homo sapiens 85-93 16367888-4 2006 RESULTS: Insulin 1 microm and rosiglitazone 10 microm markedly reduced resistin mRNA expression (relative to the control gene TF2D) by 4.7-fold (p < 0.05) and 5.3-fold (p < 0.02), respectively. Rosiglitazone 30-43 resistin Homo sapiens 71-79 16367888-6 2006 Resistin 1 microm significantly reduced maximum insulin-stimulated 2-deoxyglucose uptake in L6 cells from 634 to 383% (relative to 100% for control, p < 0.001), and co-administration of rosiglitazone had no effect on resistin-induced insulin resistance. Rosiglitazone 189-202 resistin Homo sapiens 0-8 15736108-0 2005 The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus. Rosiglitazone 15-28 resistin Homo sapiens 75-83 15736108-2 2005 We examined the effects of rosiglitazone and metformin on the plasma resistin levels in individuals with type 2 diabetes mellitus. Rosiglitazone 27-40 resistin Homo sapiens 69-77 15736108-9 2005 The plasma resistin levels decreased in the rosiglitazone group (2.49 +/- 1.93 vs 1.95 +/- 1.59 ng/ml; P < .05) but increased in the metformin group (2.61 +/- 1.69 vs 5.13 +/- 2.81 ng/ml; P < .05). Rosiglitazone 44-57 resistin Homo sapiens 11-19 15736108-11 2005 In summary, rosiglitazone treatment decreased the plasma resistin levels whereas metformin treatment increased them in patients with type 2 diabetes mellitus showing poor glycemic control with sulfonylurea therapy. Rosiglitazone 12-25 resistin Homo sapiens 57-65 15736108-13 2005 Considering the potential role of resistin in insulin resistance, decrease in resistin levels may contribute to improving insulin action with rosiglitazone treatment. Rosiglitazone 142-155 resistin Homo sapiens 34-42 15736108-13 2005 Considering the potential role of resistin in insulin resistance, decrease in resistin levels may contribute to improving insulin action with rosiglitazone treatment. Rosiglitazone 142-155 resistin Homo sapiens 78-86 15526156-5 2004 Resistin antagonizes insulin action, and it is downregulated by rosiglitazone and peroxisome proliferator-activated receptor gamma agonists. Rosiglitazone 64-77 resistin Homo sapiens 0-8 14671216-0 2003 Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. Rosiglitazone 79-92 resistin Homo sapiens 0-8 14671216-0 2003 Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. Rosiglitazone 79-92 resistin Homo sapiens 44-52 14671216-9 2003 RSG (10 nM) reduced the insulin-mediated rise in resistin protein secretion (1 nM insulin plus RSG, 971 +/- 35 pg/ml; insulin, 1 microM insulin plus RSG, 1019 +/- 28 pg/ml; P < 0.01 vs. insulin alone). Rosiglitazone 0-3 resistin Homo sapiens 49-57 14671216-12 2003 In human abdominal sc adipocytes, RSG blocks the insulin-mediated release of resistin secretion in vitro. Rosiglitazone 34-37 resistin Homo sapiens 77-85 15741250-0 2005 Resistin levels in human immunodeficiency virus-infected patients with lipoatrophy decrease in response to rosiglitazone. Rosiglitazone 107-120 resistin Homo sapiens 0-8 15741250-4 2005 Resistin concentration decreased significantly after rosiglitazone (12.17 +/- 1.15 ng/ml to 10.23 +/- 1.05 ng/ml; P = 0.02), in conjunction with significant increases in adiponectin- (P < 0.001) and insulin- stimulated glucose disposal (P = 0.004). Rosiglitazone 53-66 resistin Homo sapiens 0-8 15741250-6 2005 In summary, among HIV-infected subjects with insulin resistance and lipoatrophy, resistin levels decreased significantly after rosiglitazone. Rosiglitazone 127-140 resistin Homo sapiens 81-89